睿知中国疾病研究地图
候选清单0

北京首都医科大学

首都医科大学附属北京天坛医院

Beijing Tiantan Hospital

在本站收录的 53 种疾病中,这家医院列在其中 15 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

首都医科大学附属北京天坛医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 脊索瘤Chordoma14 篇牵头论文
  2. 骨肉瘤Osteosarcoma0 篇牵头论文
  3. 神经母细胞瘤Neuroblastoma0 篇牵头论文
  4. 血友病 AHaemophilia A1 篇牵头论文
  5. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder34 篇牵头论文牵头 2 项开放试验
  6. 重症肌无力Myasthenia gravis1 篇牵头论文
  7. 烟雾病Moyamoya disease60 篇牵头论文牵头 9 项开放试验
  8. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis6 篇牵头论文
  9. 大动脉炎Takayasu arteritis1 篇牵头论文
  10. 特发性肺纤维化Idiopathic pulmonary fibrosis2 篇牵头论文
  11. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis4 篇牵头论文
  12. 脊髓性肌萎缩症Spinal muscular atrophy0 篇牵头论文
  13. 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
  14. 尼曼-匹克病 C 型Niemann–Pick disease type C0 篇牵头论文
  15. Leber 遗传性视神经病变Leber hereditary optic neuropathy1 篇牵头论文

未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、肝细胞癌、胃癌、肝母细胞瘤、视网膜母细胞瘤、胃肠道间质瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、IgG4相关性疾病、肝豆状核变性、胆道闭锁、肝包虫病、肺淋巴管平滑肌瘤病、法布雷病、庞贝病、白塞病、Alport 综合征、IgA 肾病、戈谢病、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 14 篇,占 13.3%。

牵头论文
14
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 2220222023: 3320232024: 2220242025: 332025

北京有 11 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
论文中的科室神经外科
牵头的论文14
  1. Enhancing Chordoma Radiotherapy: Ta@PVP Nanoparticles as Potent Radiosensitizers.2025ACS applied materials & interfaces
  2. Development and validation of basement membrane-related signatures for predicting postoperative recurrence, tumor microenvironment and drug candidates in chordomas.2025BMC cancer
  3. Radiogenomic method combining DNA methylation profiles and magnetic resonance imaging radiomics predicts patient prognosis in skull base chordoma.2025Clinical epigenetics
  4. Endoplasmic reticulum stress-related cancer-associated fibroblast confers adverse prognosis and therapeutic vulnerability in skull base chordoma.2024Neuro-oncology
  5. The novel developed and validated multiparametric MRI-based fusion radiomic and clinicoradiomic models predict the postoperative progression of primary skull base chordoma.2024Scientific reports
  6. Function and regulation of miR-186-5p, miR-125b-5p and miR-1260a in chordoma.2023BMC cancer
  7. Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma.2023Clinical and translational medicine
  8. Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes.2023Clinical cancer research : an official journal of the American Association for Cancer Research
  9. Mid-term follow-up surgical results in 284 cases of clival chordomas: the risk factors for outcome and tumor recurrence.2022Neurosurgical review
  10. Survival and treatment of cranial and spinal chordomas: a population-based study.2022Neurosurgical review
  11. TGFB3 downregulation causing chordomagenesis and its tumor suppression role maintained by Smad7.2021Carcinogenesis
  12. DEPDC1B regulates the progression of human chordoma through UBE2T-mediated ubiquitination of BIRC5.2021Cell death & disease
  13. Loss of SMARCB1 promotes autophagy and facilitates tumour progression in chordoma by transcriptionally activating ATG5.2021Cell proliferation
  14. Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival.2021Nature communications
早期论文(2016–2020 年)30
  1. MRI Signal Intensity and Electron Ultrastructure Classification Predict the Long-Term Outcome of Skull Base Chordomas.2020AJNR. American journal of neuroradiology
  2. LncRNA and mRNA expression profiles reveal the potential roles of lncRNA contributing to regulating dural penetration in clival chordoma.2020Aging
  3. Mean platelet volume and platelet distribution width serve as prognostic biomarkers in skull base chordoma: a retrospective study.2020BMC cancer
  4. High expression of survivin independently correlates with tumor progression and mortality in patients with skull base chordomas.2020Journal of neurosurgery
  5. A Series of 62 Skull Base Chordomas in Pediatric and Adolescent Patients: Clinical Characteristics, Treatments, and Outcomes.2020Neurology India
  6. Natural Growth Dynamics of Untreated Skull Base Chordomas In Vivo.2020World neurosurgery
  7. Benign notochordal cell tumour: clinicopathology and molecular profiling of 13 cases.2019Journal of clinical pathology
  8. Combination of PARP inhibitor and temozolomide to suppress chordoma progression.2019Journal of molecular medicine (Berlin, Germany)
  9. High Expression of TGF-β1 Predicting Tumor Progression in Skull Base Chordomas.2019World neurosurgery
  10. Differential Diagnosis and Treatment Modality of Parasellar Plasmacytoma: Clinical Series and Literature Review.2019World neurosurgery
  11. SNF5 as a prognostic factor in skull base chordoma.2018Journal of neuro-oncology
  12. Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma.2018Neuro-oncology
  13. Aberrant Expression of Extracellular Signal-Regulated Kinase and 15-Hydroxyprostaglandin Dehydrogenase Indicates Radiation Resistance and Poor Prognosis for Patients with Clival Chordomas.2018World neurosurgery
  14. MR Imaging Grading System for Skull Base Chordoma.2017AJNR. American journal of neuroradiology
  15. Effect comparisons among treatment measures on progression-free survival in patients with skull base chordomas: a retrospective study of 234 post-surgical cases.2017Acta neurochirurgica
  16. Clinical features and surgical outcomes of patients with skull base chordoma: a retrospective analysis of 238 patients.2017Journal of neurosurgery
  17. In Reply to the Letter to the Editor Regarding "Expression of Cathepsin K in Skull Base Chordoma".2017World neurosurgery
  18. In Reply to the Letter to the Editor Regarding "Expression of Cathepsin K in Skull Base Chordoma".2017World neurosurgery
  19. In Reply to "Ki-67 Index as a Prognostic Marker in Chordomas: A Systematic Review of the Literature".2017World neurosurgery
  20. In Reply to "Prognostic Significance of Resection Degree in Skull Base Chordoma: A Systematic Review and Meta-Analysis".2017World neurosurgery
  21. Expression of Cathepsin K in Skull Base Chordoma.2017World neurosurgery
  22. Prognostic Value of a Category Based on Electron Microscopic Features of Clival Chordomas.2017World neurosurgery
  23. Clinical Features and Prognostic Factors of Children and Adolescents with Clival Chordomas.2017World neurosurgery
  24. Factors for Overall Survival in Patients with Skull Base Chordoma: A Retrospective Analysis of 225 Patients.2017World neurosurgery
  25. Differences in Dural Penetration of Clival Chordomas Are Associated with Different Prognosis and Expression of Platelet-Derived Growth Factor Receptor-β.2017World neurosurgery
  26. Factors for tumor progression in patients with skull base chordoma.2016Cancer medicine
  27. Bone invasiveness is associated with prognosis in clivus chordomas.2016Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  28. Classification and surgical approaches for transnasal endoscopic skull base chordoma resection: a 6-year experience with 161 cases.2016Neurosurgical review
  29. Analysis of Clinical Features and Outcomes of Skull Base Chordoma in Different Age-Groups.2016World neurosurgery
  30. Proposal and Validation of a Basic Progression Scoring System for Patients with Skull Base Chordoma.2016World neurosurgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm进行中,不再招募NCT07809178牵头方(推断)2026-10 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年没有牵头骨肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 48 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年没有牵头神经母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 24 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

北京有 15 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 34 篇,占 7.0%。

牵头论文
34
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 101020212022: 4420222023: 4420232024: 9920242025: 662025

北京有 12 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
    分期
    未注明
    开始
    2019-01
    登记号
    NCT04106830

    年龄 16 岁 至 75 岁(登记的条件)

    牵头:首都医科大学附属北京天坛医院北京

  2. 邀请入组
    Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)
    分期
    未注明
    开始
    2023-12
    登记号
    NCT06643858

    年龄 6 岁 至 90 岁(登记的条件)

    牵头:首都医科大学附属北京天坛医院北京

  3. 正在招募
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06413654

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心北京、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、温州、石家庄、福州、郑州、长沙

  4. 正在招募
    Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
    分期
    早期I期
    开始
    2022-04
    登记号
    NCT05145361

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心北京、天津、太原、西安

  5. 即将招募
    Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
    分期
    IV期
    开始
    2026-06
    登记号
    NCT07699770

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学唐都医院;另有 5 家列出的医院为研究中心北京、昆明、沈阳、西安、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题抗体与诊断影像急性发作治疗
论文中的科室神经内科影像/核医学科病理/检验科肾内科
牵头的论文34
  1. Serum GPR37 as a novel biomarker for disease activity, disability, and differential diagnosis in NMOSD.2026Clinica chimica acta; international journal of clinical chemistry
  2. Deep Gray Matter Iron Deposition in NMOSD and MOGAD: A Comparative Study with MS.2025Academic radiology
  3. Oligodendroglia in Neuromyelitis Optica Spectrum Disorder.2025Advances in neurobiology
  4. Spatiotemporal subtypes of brain and spinal cord atrophy in neuromyelitis optica spectrum disorders and multiple sclerosis.2025BMC medicine免费全文
  5. Diagnostic biomarkers for differentiating AQP4-IgG- negative NMOSD from other nervous system autoimmune disorders: a retrospective study.2025Frontiers in immunology免费全文
  6. Estimated Brain Age in Healthy Aging and Across Multiple Neurological Disorders.2025Journal of magnetic resonance imaging : JMRI
  7. Cerebrospinal fluid interleukin-6 may be a biomarker for conversion of clinically isolated syndrome to neuromyelitis optica spectrum disorder.2025Multiple sclerosis and related disorders
  8. Imaging Transcriptomics of Brain Functional Alterations in MS and Neuromyelitis Optica Spectrum Disorder.2024AJNR. American journal of neuroradiology免费全文
  9. Identification of potential biomarkers for neuromyelitis optica by quantitative proteomics.2024Annals of clinical and translational neurology免费全文
  10. Distinct virtual histology of grey matter atrophy in four neuroinflammatory diseases.2024Brain : a journal of neurology
  11. Efficacy and safety of apheresis therapy in AQP4 antibody-positive NMOSD attack: A propensity score-matched cohort study.2024CNS neuroscience & therapeutics免费全文
  12. The landscape of PBMCs in AQP4-IgG seropositive NMOSD and MOGAD, assessed by high dimensional mass cytometry.2024CNS neuroscience & therapeutics免费全文
  13. Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder.2024Journal of neuroimmunology
  14. Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder and multiple sclerosis.2024Journal of neurology
  15. Independent and reproducible hippocampal radiomics biomarkers for multisite multiple sclerosis and neuromyelitis optica spectrum disorders.2024Multiple sclerosis and related disorders
  16. APOE from patient-derived astrocytic extracellular vesicles alleviates neuromyelitis optica spectrum disorder in a mouse model.2024Science translational medicine
  17. Targeting chemoattractant chemokine (C-C motif) ligand 2 derived from astrocytes is a promising therapeutic approach in the treatment of neuromyelitis optica spectrum disorders.2023Frontiers in immunology免费全文
  18. Brain age gap in neuromyelitis optica spectrum disorders and multiple sclerosis.2023Journal of neurology, neurosurgery, and psychiatry
  19. Tocilizumab treatment in neuromyelitis optica spectrum disorders: Updated meta-analysis of efficacy and safety.2023Multiple sclerosis and related disorders
  20. Establishment of a comprehensive diagnostic model for neuromyelitis optica spectrum disorders based on the analysis of laboratory indicators and clinical data.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  21. The difference of the retinal structural and microvascular characteristics in patients with MOGAD-ON and AQP4-ON.2022BMC neurology免费全文
  22. A prospective study on tryptophan immunoadsorption in AQP4 antibody-positive neuromyelitis optica spectrum disorders.2022Journal of clinical apheresis
  23. Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder.2022Multiple sclerosis (Houndmills, Basingstoke, England)
  24. NMO-IgG Induce Interleukin-6 Release via Activation of the NF-κB Signaling Pathway in Astrocytes.2022Neuroscience
  25. Thymic Involution and Altered Naive CD4 T Cell Homeostasis in Neuromyelitis Optica Spectrum Disorder.2021Frontiers in immunology免费全文
  26. Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS.2021Journal of neurology, neurosurgery, and psychiatry免费全文
  27. Brain structural and functional alterations in MOG antibody disease.2021Multiple sclerosis (Houndmills, Basingstoke, England)
  28. Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.2021Multiple sclerosis and related disorders
  29. The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative Neuromyelitis Optica Spectrum Disorder: A systematic review and meta-analysis.2021Multiple sclerosis and related disorders
  30. Elevated chemokines and cytokines for eosinophils in neuromyelitis optica spectrum disorders.2021Multiple sclerosis and related disorders
  31. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.2021Multiple sclerosis and related disorders
  32. Timing of plasma exchange for neuromyelitis optica spectrum disorders: A meta-analysis.2021Multiple sclerosis and related disorders
  33. B-Cell Compartmental Features and Molecular Basis for Therapy in Autoimmune Disease.2021Neurology(R) neuroimmunology & neuroinflammation免费全文
  34. Persistently Gadolinium-Enhancing Lesion Is a Predictor of Poor Prognosis in NMOSD Attack: a Clinical Trial.2021Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics免费全文
中文论文(未计入)2
  1. [Advancements and outstanding questions in neuroimmune diseases over the past decade].2024Zhonghua nei ke za zhi
  2. [Progress in the study of the correlation between dyslipidemia and demyelinating diseases of the nervous system].2024Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)邀请入组NCT06643858牵头方2023-12 启动
  2. Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)正在招募NCT04106830牵头方2019-01 启动
  3. Sensitivity and Specificity of TSA-CBA for Autoantibodies Against Neural Antigen Determination状态不明NCT05414890牵头方2022-06 启动
  4. China National Registry of Neuro-Inflammatory Diseases状态不明NCT05154370牵头方2021-12 启动
  5. Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial即将招募NCT07699770研究中心IV期2026-06 启动
  6. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)正在招募NCT06413654研究中心II/III期2024-07 启动
  7. Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)正在招募NCT05145361研究中心早期I期2022-04 启动
  8. A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders状态不明NCT06212245研究中心IV期2024-02 启动
PubMed 以外找到的论文(未计入)5
  1. Choroid Plexus Cysts on 7T MRI Differentiate NMOSD from MS2025medRxiv预印本
  2. Development and Validation of a Differential Diagnostic Models for Guillain–Barré Syndrome Based on Clinical and Laboratory Indicators: A Retrospective Study2025Acta Neurologica Scandinavica论文
  3. Progress on single-cell sequencing technology in central nervous system autoimmune diseases2025DOAJ (DOAJ: Directory of Open Access Journals)论文
  4. A Multisite and Multimodal Comparative Study of Cerebellar Connectome Between Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders2022bioRxiv (Cold Spring Harbor Laboratory)预印本
  5. Magnetic resonance imaging markers for multiple sclerosis and neuromyelitis optica spectrum disorders2021Neurology and Clinical Neuroscience论文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

北京有 11 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
    分期
    II期
    开始
    2022-07
    登记号
    NCT05067348

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:空军军医大学唐都医院;另有 5 家列出的医院为研究中心上海、北京、天津、成都、西安、长沙

  2. 正在招募
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    分期
    III期
    开始
    2021-07
    登记号
    NCT04951622

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、济南、福州、西安、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 60 篇,占 16.9%。

牵头论文
60
2021–2025 年
牵头试验
15
任何状态,ClinicalTrials.gov
牵头的开放试验
9
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 111120212022: 6620222023: 111120232024: 131320242025: 19192025

北京有 8 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

这家医院参与的开放试验 9

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of Ischemic Preconditioning Therapy Versus Optimal Medical Therapy in Reducing the Recurrence of Ischemic Events in Symptomatic Moyamoya Disease
    分期
    不分期
    开始
    2026-10
    登记号
    NCT07889531

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:首都医科大学附属北京天坛医院北京

  2. 正在招募
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    分期
    未注明
    开始
    2026-08
    登记号
    NCT07894107

    年龄 12 岁 至 70 岁(登记的条件)

    牵头:首都医科大学附属北京天坛医院;另有 12 家列出的医院为研究中心上海、北京、南昌、成都、杭州、武汉、苏州、郑州

  3. 正在招募
    Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease
    分期
    未注明
    开始
    2024-12
    登记号
    NCT06817434

    年龄 18 岁 至 60 岁(登记的条件)

    牵头:首都医科大学附属北京天坛医院北京

  4. 正在招募
    Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease
    分期
    未注明
    开始
    2024-12
    登记号
    NCT06832839

    年龄 18 岁 至 60 岁(登记的条件)

    牵头:首都医科大学附属北京天坛医院北京

  5. 正在招募
    Family-Based Moyamoya Susceptibility and Early Detection
    分期
    未注明
    开始
    2024-11
    登记号
    NCT07517354

    年龄未注明(登记的条件)

    牵头:首都医科大学附属北京天坛医院;另有 1 家列出的医院为研究中心北京

  6. 正在招募
    Functional Magnetic Resonance-Based Observations of Brain Networks in Moyamoya Disease Patients Under Anesthesia
    分期
    未注明
    开始
    2023-10
    登记号
    NCT06041659

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:首都医科大学附属北京天坛医院北京

  7. 正在招募
    Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)
    分期
    未注明
    开始
    2022-05
    登记号
    NCT05332756

    年龄 2 岁 至 60 岁(登记的条件)

    牵头:首都医科大学附属北京天坛医院北京

  8. 正在招募
    Registry of Multicenter Brain-Heart Comorbidity in China
    分期
    未注明
    开始
    2012-01
    登记号
    NCT05961748

    年龄 18 岁 至 未注明(登记的条件)

    牵头:首都医科大学附属北京天坛医院;另有 4 家列出的医院为研究中心上海、北京、哈尔滨、郑州

  9. 即将招募
    Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moyamoya Disease.
    分期
    不分期
    开始
    2026-07
    登记号
    NCT07762547

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:首都医科大学附属北京天坛医院北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像与脑血流中风与出血血管重建手术
论文中的科室神经外科影像/核医学科
牵头的论文60
  1. Integrated bulk RNA sequencing and mass cytometry analysis reveal the circulating immune landscape in ischemic and hemorrhagic Moyamoya disease.2025BMC immunology免费全文
  2. Serum Creatine Levels as a Predictive Factor for Postoperative Cerebrovascular Events in Patients With Moyamoya Disease.2025Brain and behavior免费全文
  3. Unraveling the Dyslipidemic Landscape in Moyamoya Disease: OxLDL as a Key Biomarker.2025CNS neuroscience & therapeutics免费全文
  4. Taurine levels and long-term adverse cerebrovascular risk in moyamoya disease: A prognostic perspective study.2025Clinical nutrition (Edinburgh, Scotland)
  5. Innate Immune Cell Profiling in Peripheral Blood Mononuclear Cells of Patients with Moyamoya Disease.2025Inflammation
  6. Circulating T cell atlas in Moyamoya disease: insights into immunopathogenesis of cerebrovascular disorders.2025Journal of neuroinflammation免费全文
  7. Serum amyloid A2-induced phenotypic switching of vascular smooth muscle cells in moyamoya disease.2025Journal of neurosurgery
  8. Improvement in multiple cognitive domains via combined revascularization by 6 months' follow-up: a new potential surgical indication in moyamoya disease.2025Journal of neurosurgery
  9. RNF213 Variant and Infectious Burden Associated With Intracranial Artery Stenosis in Moyamoya Disease.2025Journal of the American Heart Association免费全文
  10. Comprehensive Analysis and In Vitro Verification of Endothelial-Mesenchymal Transition-Related Genes in Moyamoya Disease.2025Molecular neurobiology
  11. Choroid plexus enlargement correlates with cognitive dysfunction and disease progression in Moyamoya disease.2025Neurosurgical review
  12. Angiogenesis-related genes and immune microenvironment in moyamoya disease: a transcriptomic and functional analysis.2025Orphanet journal of rare diseases免费全文
  13. Deep-learning tool for early identification of non-traumatic intracranial hemorrhage etiology and application in clinical diagnostics based on computed tomography (CT) scans.2025PeerJ免费全文
  14. Reorganization of gray matter networks in patients with Moyamoya disease.2025Scientific reports免费全文
  15. Understanding external carotid artery collateralisation after cerebral revascularisation in moyamoya disease: insights from quantitative analysis.2025Stroke and vascular neurology免费全文
  16. Association Between Folate Metabolism Risk, Collateral Circulation, and Hemorrhagic Risk in Moyamoya Disease.2025Translational stroke research
  17. Alterations in the Glymphatic System and Association with Brain Structure and Cognitive Function in Moyamoya Disease.2025Translational stroke research
  18. Glymphatic Impairment Associated with Neurocognitive Dysfunction in Moyamoya Disease.2025Translational stroke research
  19. Age-Dependent Risk Factors for Hemorrhagic Events in Moyamoya Disease: The Role of Collateral Vessels.2025World neurosurgery
  20. Differential WNT4 expression among various subtypes of moyamoya disease results in alterations of microtubule stability.2024Clinical and translational medicine免费全文
  21. Circulating immune cell landscape and T-cell abnormalities in patients with moyamoya disease.2024Clinical and translational medicine免费全文
  22. Association of lysine pathway metabolites with moyamoya disease.2024Clinical nutrition (Edinburgh, Scotland)
  23. Mass cytometry revealed the circulating immune cell landscape across different Suzuki stages of Moyamoya disease.2024Immunologic research免费全文
  24. A novel system for evaluating collateralization of the external carotid artery after cerebral revascularization in moyamoya disease.2024Journal of neurosurgery
  25. Effectiveness of indirect revascularization for adult hemorrhagic moyamoya disease: a 10-year follow-up study.2024Journal of neurosurgery
  26. Nonalcoholic fatty liver disease is an independent risk factor for ischemic stroke after revascularization in patients with Moyamoya disease: a prospective cohort study.2024Lipids in health and disease免费全文
  27. Prognostic value of morphology and hemodynamics in moyamoya disease for long-term outcomes and disease progression.2024Scientific reports免费全文
  28. Characterization of PANoptosis-related genes and the immune landscape in moyamoya disease.2024Scientific reports免费全文
  29. A Vessel Wall MRI Investigation in Patients With Moyamoya or Quasi-Moyamoya Disease: Diagnosis, Features, and Outcomes.2024The Journal of craniofacial surgery
  30. Nomogram to Predict Good Neoangiogenesis After Indirect Revascularization Surgery in Patients with Moyamoya Disease: a Case-control Study.2024Translational stroke research
  31. Risk Factors for Specific Postoperative Ischemic Complications in Patients with Moyamoya Disease: A Single-Center Retrospective Study.2024Turkish neurosurgery
  32. Long-Term Clinical Outcomes After Cerebral Revascularization in Moyamoya Disease With Extracranial Internal Carotid Artery Occlusion.2024World neurosurgery
  33. The prognostic nutrition index is a predictor for long-term outcomes after revascularization in adult moyamoya disease.2023Acta neurochirurgica
  34. Association between systemic immune-inflammatory markers and the risk of moyamoya disease: a case-control study.2023Annals of medicine免费全文
  35. Integrated analysis of the association between methionine cycle and risk of moyamoya disease.2023CNS neuroscience & therapeuticsRCT免费全文
  36. Metabolomic signatures associated with pathological angiogenesis in moyamoya disease.2023Clinical and translational medicine免费全文
  37. Application of Induced Pluripotent Stem Cells in Moyamoya Disease: Progress and Promises.2023Current stem cell research & therapy
  38. Gut microbiota in adults with moyamoya disease: characteristics and biomarker identification.2023Frontiers in cellular and infection microbiology免费全文
  39. RNA profiling of sEV (small extracellular vesicles)/exosomes reveals biomarkers and vascular endothelial dysplasia with moyamoya disease.2023Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism免费全文
  40. Fetal posterior cerebral artery in pediatric and adult moyamoya disease: A single-center experience of 480 patients.2023Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
  41. Association between DIAPH1 variant and posterior circulation involvement with Moyamoya disease.2023Scientific reports免费全文
  42. Upregulated Cytoskeletal Proteins Promote Pathological Angiogenesis in Moyamoya Disease.2023Stroke
  43. Hemorrhage Risk in Moyamoya Disease with Fetal-Type Posterior Cerebral Artery: A Propensity Score-Matched Analysis.2023World neurosurgery
  44. Predictors of preoperative cognitive dysfunction in adults with Moyamoya disease: a preliminary research.2022BMC neurology免费全文
  45. Recurrent Artery of Heubner Aneurysm Masquerading as Caudate Hemorrhage without Subarachnoid Hemorrhage in Moyamoya Disease: A Case Report and Literature Review.2022Current medical imaging
  46. Infarction Patterns and Recurrent Adverse Cerebrovascular Events in Moyamoya Disease.2022Disease markers免费全文
  47. Epigenome-Wide Association Study Reveals Differential Methylation Sites and Association of Gene Expression Regulation with Ischemic Moyamoya Disease in Adults.2022Oxidative medicine and cellular longevity免费全文
  48. Association of RNF213 Variants With Periventricular Anastomosis in Moyamoya Disease.2022Stroke
  49. Assessment of Surgical Outcomes in Children and Adult Ischemic Moyamoya Disease and Its Relationship with the Pre-infarction Cerebral Perfusion Status.2022Turkish neurosurgery
  50. Intraoperative transit-time ultrasonography combined with FLOW800 predicts the occurrence of cerebral hyperperfusion syndrome after direct revascularization of Moyamoya disease: a preliminary study.2021Acta neurochirurgica
  51. Risk factors for postoperative ischemic complications in pediatric moyamoya disease.2021BMC neurology免费全文
  52. Changes of cerebral cortical structure and cognitive dysfunction in "healthy hemisphere" after stroke: a study about cortical complexity and sulcus patterns in bilateral ischemic adult moyamoya disease.2021BMC neuroscience免费全文
  53. Impairments in brain perfusion, executive control network, topological characteristics, and neurocognition in adult patients with asymptomatic Moyamoya disease.2021BMC neuroscience免费全文
  54. Clinical Implications of the "Brush Sign" in Susceptibility-Weighted Imaging for Moyamoya Disease.2021Cerebrovascular diseases (Basel, Switzerland)
  55. Assessment of blood supply of the external carotid artery in moyamoya disease using super-selective pseudo-continuous arterial spin labeling technique.2021European radiology
  56. Letter to the Editor Regarding "Clinical Prediction of Surgical Revascularization Outcome in Moyamoya Disease Via Transcranial Color Sonography".2021Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
  57. Hyperhomocysteinemia is a risk factor for postoperative ischemia in adult patients with moyamoya disease.2021Neurosurgical review
  58. Intraoperative local hemodynamic quantitative analysis of direct revascularization in patients with moyamoya disease.2021Neurosurgical review
  59. Effects and safety of aspirin use in patients after cerebrovascular bypass procedures.2021Stroke and vascular neurology免费全文
  60. Haemodynamic analysis of adult patients with moyamoya disease: CT perfusion and DSA gradings.2021Stroke and vascular neurology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)17
  1. Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moyamoya Disease.即将招募NCT07762547牵头方不分期2026-07 启动
  2. Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome正在招募NCT07894107牵头方2026-08 启动
  3. Efficacy and Safety of Ischemic Preconditioning Therapy Versus Optimal Medical Therapy in Reducing the Recurrence of Ischemic Events in Symptomatic Moyamoya Disease正在招募NCT07889531牵头方不分期2026-10 启动
  4. Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease正在招募NCT06832839牵头方2024-12 启动
  5. Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease正在招募NCT06817434牵头方2024-12 启动
  6. Family-Based Moyamoya Susceptibility and Early Detection正在招募NCT07517354牵头方2024-11 启动
  7. Functional Magnetic Resonance-Based Observations of Brain Networks in Moyamoya Disease Patients Under Anesthesia正在招募NCT06041659牵头方2023-10 启动
  8. Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)正在招募NCT05332756牵头方2022-05 启动
  9. Registry of Multicenter Brain-Heart Comorbidity in China正在招募NCT05961748牵头方2012-01 启动
  10. Prognostic Prediction Model in Patients With Moyamoya Disease Undergoing Revascularization Surgery状态不明NCT06051552牵头方2023-10 启动
  11. Gut Microbiota in Patients With Moyamoya Disease状态不明NCT04890782牵头方2021-05 启动
  12. The Role of m6A RNA Modification in Moyamoya Disease状态不明NCT04696094牵头方2021-01 启动
  13. RNF213 Variants and Collateral Vessels in Moyamoya Disease已完成NCT04906564牵头方2019-01 启动
  14. Effects of Remote Ischemic Pre-Conditioning in Moyamoya Disease Patients已暂停NCT04064658牵头方不分期2019-10 启动
  15. Direct Bypass Versus Indirect Bypass in Treatment of Adults Hemorrhagic Moyamoya Disease状态不明NCT02982135牵头方(推断)不分期2016-01 启动
  16. NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events状态不明NCT04205578研究中心III期2020-01 启动
  17. Precision Bypass in Patients With Moyamoya Disease已撤回NCT03516851研究中心不分期2018-08 启动
PubMed 以外找到的论文(未计入)7
  1. Divergent Phenotypes and Persistent Disability: A Comparative Cohort Study of Arterial Ischaemic and Haemorrhagic Stroke in Chinese Paediatric Patients2025Psycho-Oncologie论文
  2. 甘油三酯-葡萄糖指数在烟雾病患者中的特征分析:1项病例对照研究(Analysis of Triglyceride-Glucose Index Characteristics in Patients with Moyamoya Disease: A Case-Control Study)2025DOAJ (DOAJ: Directory of Open Access Journals)论文
  3. RNA methylation-driven molecular subtypes and immune infiltration in Moyamoya disease2024Gene Reports论文
  4. Deep Learning Approach to Predict Hemorrhage in Moyamoya Disease2023arXiv (Cornell University)预印本
  5. Deep-Learning Tool for Early Identifying Non-Traumatic Intracranial Hemorrhage Etiology based on CT Scan2023arXiv (Cornell University)预印本
  6. Short⁃term neurological function and clinical symptom improvement after cerebral revascularization in adults with moyamoya disease: a single⁃center study2022DOAJ (DOAJ: Directory of Open Access Journals)论文
  7. A Practical Questionnaire and Literature Review: Dose Suzuki Grading Still the Gold Standard for the Diagnosis of Moyamoya Disease?2021Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 6 篇,占 2.3%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 2220232024: 0020242025: 112025

北京有 13 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科影像/核医学科
牵头的论文6
  1. Clinical and imaging features and treatment response of anti-NMDAR encephalitis combined with MOGAD.2025Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  2. Typical metabolic pattern of 18F-FDG PET in Anti-NMDAR encephalitis in the acute and subacute phases and its correlation with T2 FLAIR-MRI features.2023BMC neuroscience
  3. Elevated blood and cerebrospinal fluid biomarkers of microglial activation and blood‒brain barrier disruption in anti-NMDA receptor encephalitis.2023Journal of neuroinflammation
  4. Positron emission tomography in autoimmune encephalitis: Clinical implications and future directions.2022Acta neurologica Scandinavica
  5. The prognosis of late-onset anti-N-methyl-D-aspartate receptor encephalitis in China.2022Acta neurologica Scandinavica
  6. Aberrant multimodal brain networks in patients with anti-NMDA receptor encephalitis.2021CNS neuroscience & therapeutics
早期论文(2016–2020 年)4
  1. Anti-NMDA receptor encephalitis concomitant with myelin oligodendrocyte glycoprotein antibody diseases: A retrospective observational study.2020Medicine
  2. Reply.2018AJNR. American journal of neuroradiology
  3. Brain MRI Characteristics of Patients with Anti-N-Methyl-D-Aspartate Receptor Encephalitis and Their Associations with 2-Year Clinical Outcome.2018AJNR. American journal of neuroradiology
  4. Paraneoplastic Anti-N-Methyl-D-Aspartic Acid Receptor Encephalitis.2017Chinese medical journal
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis进行中,不再招募NCT05503264研究中心III期2022-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

北京有 30 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

北京有 27 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.5%。

牵头论文
4
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 112025

北京有 19 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
    分期
    I期
    开始
    2024-12
    登记号
    NCT06556394

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、成都、杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室神经内科神经外科
牵头的论文4
  1. The difference between cystatin C- and creatinine-based estimated glomerular filtration rate and survival in amyotrophic lateral sclerosis: a population-based cohort study.2026Neurodegenerative disease management
  2. Genetic evidence for the liver-brain axis: lipid metabolism and neurodegenerative disease risk.2025Lipids in health and disease
  3. Amyotrophic lateral sclerosis and myasthenia gravis overlaps syndrome: a series of case report.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  4. Analysis of lncRNAs profiles associated with ferroptosis can predict prognosis and immune landscape and drug sensitivity in patients with clear cell renal cell carcinoma.2023Journal of biochemical and molecular toxicologyRCT
早期论文(2016–2020 年)2
  1. NEK1 and GRN mutations coexist in a sporadic Chinese Hui descent ALS patient.2020Amyotrophic lateral sclerosis & frontotemporal degeneration
  2. Needle electromyography of the frontalis muscle in patients with amyotrophic lateral sclerosis.2016Muscle & nerve
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. Tofacitinib in Patients With Amyotrophic Lateral Sclerosis即将招募NCT06689982牵头方早期I期2024-12 启动
  2. Safety and Tolerance of RAG-17 in Amyotrophic Lateral Sclerosis Patients With SOD1 Gene Mutation已完成NCT05903690牵头方早期I期2023-05 启动
  3. Safety and Preliminary Efficacy of Aleeto in Amyotrophic Lateral Sclerosis状态不明NCT06181526牵头方I期2023-12 启动
  4. Amyotrophic Lateral Sclerosis Registry状态不明NCT05892822牵头方(推断)2023-06 启动
  5. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation正在招募NCT06556394研究中心I期2024-12 启动
  6. A Phase II Study of ALT001 in Patients With Amyotrophic Lateral Sclerosis (ALS)即将招募NCT07833618研究中心II期2026-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊髓性肌萎缩症

Spinal muscular atrophy

2021–2025 年没有牵头脊髓性肌萎缩症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

北京有 8 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
    分期
    I/II期
    开始
    2024-05
    登记号
    NCT06421831

    年龄 2 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients正在招募NCT06421831研究中心I/II期2024-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

北京有 11 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

尼曼-匹克病 C 型

Niemann–Pick disease type C

2021–2025 年没有牵头尼曼-匹克病 C 型的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 3 家医院列在尼曼-匹克病 C 型下全国有 15 家医院列在尼曼-匹克病 C 型下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尼曼-匹克病 C 型开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Leber 遗传性视神经病变

Leber hereditary optic neuropathy

2021–2025 年中国大陆作者发表的 52 篇Leber 遗传性视神经病变 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.9%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

北京有 3 家医院列在Leber 遗传性视神经病变下全国有 32 家医院列在Leber 遗传性视神经病变下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Leber 遗传性视神经病变开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

首都医科大学附属北京天坛医院

Beijing Tiantan Hospital

北京

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Beijing Neurosurgical Institute and Beijing Tiantan Hospital; Jing-Jin Center for Neuroinfalmmation Beijing Tiantan Hospital; Tiantan Hospital Affiliated to Capital Medical University; Beijing Tiantan Hospital Affiliated to Capital Medical University; A.L.) and Beijing Tiantan Hospital (F.P; Beijing Tiantan Hospital Capital Medical University; Beijing Tiantan Hospital Affiliated with Capital Medical University; Beijing Tiantan Hospital of Capital Medical University

提出更正下载数据